Evidence map›Paper›PMID 40682727›Full record

ArticleBiological trace element research2026

Boric Acid and Hyperthermia Combination: A New Cancer Therapy in The Human Hepatocellular Carcinoma and Neuroblastoma?

Okan Sancer, Uğur Şahin, Vehbi Atahan Toğay, Pınar Aslan Koşar

Abstract read
PubMed Publisher
In one paragraph

Article in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Okan SancerInnovative Technologies Application and Research Center, Genetic Research Unit, Suleyman Demirel University, 32260, Isparta, Türkiye. okansancer@hotmail.com.
Uğur ŞahinInnovative Technologies Application and Research Center, Genetic Research Unit, Suleyman Demirel University, 32260, Isparta, Türkiye.ORCID http://orcid.org/0000-0002-5629-3485
Vehbi Atahan ToğayFaculty of Medicine, Department of Medical Biology, Suleyman Demirel University, Isparta, Türkiye.ORCID http://orcid.org/0000-0003-4722-3845
Pınar Aslan KoşarFaculty of Medicine, Department of Medical Biology, Suleyman Demirel University, Isparta, Türkiye.ORCID http://orcid.org/0000-0003-2602-5145

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Boric acid (BA) has gained attention as a potential micronutrient due to its critical cellular roles, including its apoptotic effects on various cancer cell types. Hyperthermia (HT), depending on the type of cancer, has also been shown to enhance therapeutic efficacy. This study aims to investigate the combined effects of BA and hyperthermia on HepG2 and SH-SY5Y cancer cell lines. The half-maximal inhibitory concentration (IC₅₀) of BA was first determined to assess its impact on cell viability and proliferation. IC

Indexed as

Boric AcidsCarcinoma, HepatocellularHyperthermia, InducedLiver NeoplasmsNeuroblastomaApoptosisCell Line, TumorCell ProliferationCell SurvivalCombined Modality TherapyDNA DamageHep G2 CellsHumansboric acidBoric AcidsBoric acidComet assayGene expressionHepatocellular carcinoma HyperthermiaNeuroblastoma

Identifiers

PMID40682727

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.